OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Almac Group confirms it has supported Agios Pharmaceuticals, Inc., in the clinical trial and commercial launch of PYRUKYND® (mitapivat).
The treatment is the first FDA approved, disease-modifying therapy for adults with hemolytic anemia caused by PK (pyruvate kinase) deficiency, a rare, debilitating, and lifelong form of anemia.
Read more about the work between Almac Group and Agios here.